SBIR/STTR Research Award

Depot intra-articular fluticasone for the treatment of arthritis

Award identifier 62ff4139e6b3d4d818c82cf0a976cfbd11ffa217cc0dbf844156dd6f8e0a4bccAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,191,901

Program and phase

SBIR · Phase II

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AURITEC PHARMACEUTICALS, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
QX8KP6JKQ2L8
Solicitation number
PA12-088
Topic code
NIAMS

Research abstract

DESCRIPTION (provided by applicant): The broad long-term goal of this research is to reduce morbidity due to arthritis by developing long-lasting injectable intra-articular drug delivery systems. Intra-articular steroids have been a mainstay of treatment for arthritis for more than 50 years. However, for many patients, multiple steroid injections are necessary. We have developed a series of steroid delivery systems that deliver steroid at therapeutic levels in the eye for as long as 3 years from a single implantation. We believe that the development of an injectable intra-articular sustained release steroid delivery formulation that releases drug over a prolonged period is readily achievable, and that this formulation will become a useful tool in the treatment of arthritis. We achieved the specific aims of Phase I of this proposal which were to formulate sustained- release suspensions for an intra-articular steroid, to test the in vitro releae characteristics of these formulations, and to test the in vivo pharmacokinetics and safety of the formulations in sheep. The specific aims of this Phase II proposal are to confirm efficacy in an animal model of synovial inflammatory disease; to determine the minimum dose required using a dose ranging efficacy study; tomanufacture a lead formulation under sufficient Good Manufacturing Procedures (GMP) to permit Phase 1 clinical studies under an Investigational New Drug (IND) Exemption; and to contract pre-clinical GLP animal studies in sheep to support the IND. The milestone for the successful completion of Phase II work is the demonstration of efficacy in the rat model and safety of our target dose in sheep. In Phase IIb of this grant we wil complete necessary pre- clinical studies and submit an IND to the FDA. We have experience in all aspects of the drug development process from laboratory expertise, to regulatory experience, to a history of partnerships with two corporate partners leading to two NDAs. Because the technology is sound, the preliminary data are supportive, the development strategy is straightforward, and because we have done this before, we are confident that the probability of success is high. We believe that the resulting product can compete effectively in the niche market currently occupied by the viscosupplements. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: For more than 50 years intra-articular injection of steroids has been a mainstay of the treatment of arthritis. We propose to develop a formulation of a steroid that will be more effective, and require fewer injections at less frequent intervals. We've demonstrated in Phase 1 of this project that sustained levels are maintained in animal models compared to existing formulations. Successful completion of this work will lead to the development of new treatments for large numbers of patients.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

30 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $25,454,161. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.